Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report.

Background And Purpose: Oral fingolimod 0.5 mg daily was approved in the European Union in 2011 for the treatment of relapsing multiple sclerosis in the aggressive form and as a second line treatment in patients with high disease activity despite interferon beta therapy. The aim of this study was the evaluation of efficacy, safety and tolerance of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) during a 12-month observation period.

[Epileptic seizures as a manifestation of brain tumors: clinical and electroencephalographic correlations].

Epilepsy may be the earliest and the sole clinical manifestation of brain tumours. Different studies present epileptic seizures as the first symptom of a brain tumours in adults in approximately 30-40% of cases and in children from 1-10%. In order to evaluate the incidence of epileptic seizures in children versus adults with brain tumors, we investigated the group of 113 children and 578 adults who were hospitalized at the Departments of Neurology and Developmental Neurology between 1990-1999.